Celgene’s Revlimid Gains Blockbuster Status; Vidaza Poised To Gobble MDS Market Share
This article was originally published in The Pink Sheet Daily
Executive Summary
NICE posts positive recommendation for Vidaza payment in England, Wales.
You may also be interested in...
Celgene's Solid Quarter Enhanced By Strong Interim Data For Revlimid
A pivotal trial to expand labeling to first-line multiple myeloma therapy was stopped after the first interim data readout due to strong PFS data.
Celgene's Solid Quarter Enhanced By Strong Interim Data For Revlimid
A pivotal trial to expand labeling to first-line multiple myeloma therapy was stopped after the first interim data readout due to strong PFS data.
Celgene Awaits FDA Nod To Relaunch Vidaza With Survival Labeling
Move capitalizes on failure of Eisai’s Dacogen to show a survival benefit in elderly MDS patients.